Medicare’s $50 GLP-1 Bridge: Who Qualifies and How to Get Treated

Medicare is starting a short-term program that may make certain weight-loss GLP-1 medications more affordable for some Medicare Part D beneficiaries. The Medicare GLP-1 Bridge begins July 1, 2026 and runs through December 31, 2027.

Practical takeaway: if you meet the program requirements, your prescriber can request prior authorization. If approved, the program uses a $50 copay per month for eligible GLP-1 drugs furnished under the demonstration.

What is the Medicare GLP-1 Bridge?

CMS describes the Medicare GLP-1 Bridge as a short-term demonstration that provides eligible Part D beneficiaries access to certain GLP-1 drugs outside the usual Part D benefit coverage and payment flow. CMS says that’s part of why the program can offer a predictable $50 copay.

Step 1: Are you in an eligible Part D plan type?

CMS says only certain Medicare Part D plan types qualify for Bridge access. In general, beneficiaries must be enrolled in a standalone prescription drug plan (PDP) or an MA coordinated care plan with prescription drug coverage (MA-PD) that offers Part D coverage in CY 2026.

CMS also lists some Medicare arrangements that are not eligible unless the beneficiary is also in an eligible standalone PDP (for example, some private fee-for-service plan types and some specialized arrangements). If you’re unsure, ask your plan or your clinician’s billing/support team.

Who qualifies under CMS clinical criteria?

CMS says eligibility is based on what your prescriber submits in the prior authorization request. The prescriber must attest that you meet all criteria below at the time you initiated GLP-1 therapy (including if you started before joining Part D or before the July 1, 2026 launch).

Age: at least 18 years old.
Purpose of the prescription: the requested GLP-1 is prescribed to reduce excess body weight and maintain weight reduction, along with current and ongoing lifestyle modification (including structured nutrition and physical activity) consistent with the applicable FDA-approved label.
BMI + qualifying health conditions (choose one pathway):
- BMI ≥ 35 at initiation, or
- BMI ≥ 30 at initiation plus at least one of:
  - Heart failure with preserved ejection fraction
  - Uncontrolled hypertension (defined by CMS as systolic > 140 mm Hg or diastolic > 90 mm Hg despite concurrent treatment with two antihypertensive medications)
  - Chronic kidney disease stage 3a or above
- BMI ≥ 27 at initiation plus at least one of:
  - Pre-diabetes (as defined by American Diabetes Association guidance)
  - Previous myocardial infarction
  - Previous stroke
  - Symptomatic peripheral artery disease

Which GLP-1 weight-loss options are included?

CMS says the Bridge covers eligible GLP-1 drugs used to reduce excess body weight and maintain weight reduction:

Foundayo®
Wegovy® (injection and tablets)
Zepbound® (KwikPen®)

CMS also notes:

Zepbound® formulations not included: the single-dose vial and single-dose pen formulations are not available through the Bridge.
Pen needles: pen needles for Zepbound® KwikPen® are not covered under the Bridge, and CMS says patients can purchase them separately.

How treatment works in practice

CMS says Bridge access depends on a prescriber-submitted prior authorization request:

Your provider submits a prior authorization request using the Medicare GLP-1 Bridge prior authorization form (CMS says requests are accepted electronically or by fax).
CMS says that after a pharmacy transmits the claim and determines prior authorization is required, the pharmacy sends the authorization request to the prescriber typically within 24–72 hours.
CMS says approval or denial is sent to the patient and sent to the prescriber within 72 hours of submission.
If incorrect information was entered or updated documentation is needed, CMS says the prescriber may resubmit the form; CMS also states there is no appeals process under the Bridge.

Key exclusions: when the Bridge may not apply

CMS says the Medicare GLP-1 Bridge was designed for beneficiaries who seek GLP-1s solely to reduce excess body weight or maintain weight reduction.

CMS also says certain indications are covered through Part D (so beneficiaries are ineligible to receive those GLP-1s through the Bridge even if they meet the Bridge BMI criteria), including:

Type 2 diabetes
Moderate to severe obstructive sleep apnea
Noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)

Cost and expectations (what the $50 copay does—and doesn’t—mean)

$50 copay: CMS says eligible beneficiaries will have a $50 copay for GLP-1 drugs furnished under the Medicare GLP-1 Bridge.
Not handled like regular Part D copays: CMS says the Part D deductible does not apply.
TrOOP: CMS says no part of the $50 copay counts toward TrOOP.
No LIS for these Bridge drugs: CMS says there is no low-income subsidy (LIS) provided for LIS beneficiaries for these Bridge drugs.

Time limit matters: the demonstration is scheduled to operate through Dec. 31, 2027. What happens after that—continuation, expansion, or changes—is not guaranteed by the program.

What readers can do next

Confirm plan eligibility: check whether your Part D coverage is in an eligible plan type for CY 2026 Bridge access (ask your plan or clinician).
Bring accurate documentation: your clinician will need to submit a prior authorization request with required attestation elements tied to BMI at the time GLP-1 therapy was initiated and the weight-management purpose.
Keep obesity care “whole-person”: CDC emphasizes discussing weight and treatment options with a health care provider, and structured follow-up matters when medications are used.

Bottom line

Starting July 1, 2026, the Medicare GLP-1 Bridge is a time-limited program that can provide eligible Medicare Part D beneficiaries access to certain FDA-approved weight-loss GLP-1 drugs with a $50/month copay—but eligibility depends on both Part D plan type and CMS clinical criteria, and it requires a prescriber prior authorization process.

Key sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.